1h Free Analyst Time
The sexually transmitted diseases (STD) treatment market is poised to grow by $13.48 bn during 2022-2026, accelerating at a CAGR of 4.27% during the forecast period. The report on the sexually transmitted diseases (STD) treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis of the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence of STDs, the presence of favorable reimbursement policies, and increased initiatives by governments worldwide.
The sexually transmitted diseases (STD) treatment market analysis includes the type segment and geographic landscape.
The sexually transmitted diseases (STD) treatment market is segmented as below:
By Type
- Viral infections
- Bacterial infections
- Other infections
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the sexually transmitted diseases (STD) treatment market covers the following areas:
- Sexually transmitted diseases (STD) treatment market sizing
- Sexually transmitted diseases (STD) treatment market forecast
- Sexually transmitted diseases (STD) treatment market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by Type
6 Customer Landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
List of Exhibits
Executive Summary
The publisher recognizes the following companies as the key players in the global sexually transmitted diseases (STD) treatment market: AbbVie Inc., Affymetrix, Aurobindo Pharma Ltd., Becton Dickinson and Co., Bristol Myers Squibb Co., C. H. Boehringer Sohn AG and Co. KG, Cepheid Inc., DiaSorin SpA, Dynavax Technologies Corp., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Hologic Inc., Inovio Pharmaceuticals Inc., Johnson and Johnson, Lee's Pharmaceutical Holdings Ltd., Lupin Ltd, Merck and Co. Inc., Mylan N.V, and Pfizer Inc.Commenting on the report, an analyst from the research team said: `The latest trend gaining momentum in the market is the advance in rapid diagnosis of STDs.`
According to the report, one of the major drivers for this market is the increasing prevalence of STDs.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Affymetrix
- Aurobindo Pharma Ltd.
- Becton Dickinson and Co.
- Bristol Myers Squibb Co.
- C. H. Boehringer Sohn AG and Co. KG
- Cepheid Inc.
- DiaSorin SpA
- Dynavax Technologies Corp.
- F. Hoffmann La Roche Ltd.
- Gilead Sciences Inc.
- GlaxoSmithKline Plc
- Hologic Inc.
- Inovio Pharmaceuticals Inc.
- Johnson and Johnson
- Lee's Pharmaceutical Holdings Ltd.
- Lupin Ltd
- Merck and Co. Inc.
- Mylan N.V
- Pfizer Inc.
